[
    {
        "id": "wiki20220301en041_5978",
        "title": "BCR",
        "content": "Transport Brent Cross Railway, former name of North and West London Light railway British Columbia Railway, former name of BC Rail Beijing Suburban Railway also known as Beijing City Rail (BCR) Radio Belfast Community Radio, a radio station that broadcast in Belfast, Northern Ireland which relaunched as Belfast CityBeat in 1996 107.4 BCR FM, a radio station based in Bridgwater, Somerset, England which relaunched as Quay West 107.4 Big City Radio, a radio station based in Birmingham, England Science and Technology B-cell receptor, a transmembrane receptor protein Base curve radius, a parameter of a contact lens BCR (gene), the breakpoint cluster region protein Biochemical recurrence, for example in prostate cancer Barcode recognition, a form of automatic identification and data capture.",
        "contents": "BCR. Transport Brent Cross Railway, former name of North and West London Light railway British Columbia Railway, former name of BC Rail Beijing Suburban Railway also known as Beijing City Rail (BCR) Radio Belfast Community Radio, a radio station that broadcast in Belfast, Northern Ireland which relaunched as Belfast CityBeat in 1996 107.4 BCR FM, a radio station based in Bridgwater, Somerset, England which relaunched as Quay West 107.4 Big City Radio, a radio station based in Birmingham, England Science and Technology B-cell receptor, a transmembrane receptor protein Base curve radius, a parameter of a contact lens BCR (gene), the breakpoint cluster region protein Biochemical recurrence, for example in prostate cancer Barcode recognition, a form of automatic identification and data capture.",
        "wiki_id": "1387785"
    },
    {
        "id": "wiki20220301en004_21196",
        "title": "Prostate cancer",
        "content": "The D'Amico classification stratifies men by low, intermediate, or high risk based on stage, grade and PSA. It is used widely in clinical practice and research settings. The major downside to the three-level system is that it does not account for multiple adverse parameters (e.g., high Gleason score and high PSA) in stratifying patients. The Partin tables predict pathologic outcomes (margin status, extraprostatic extension, and seminal vesicle invasion) based on the same three variables and are published as lookup tables. The Kattan nomograms predict recurrence after surgery and/or radiation therapy, based on data available at the time of diagnosis or after surgery. The Kattan score represents the likelihood of remaining free of disease at a given time interval following treatment.",
        "contents": "Prostate cancer. The D'Amico classification stratifies men by low, intermediate, or high risk based on stage, grade and PSA. It is used widely in clinical practice and research settings. The major downside to the three-level system is that it does not account for multiple adverse parameters (e.g., high Gleason score and high PSA) in stratifying patients. The Partin tables predict pathologic outcomes (margin status, extraprostatic extension, and seminal vesicle invasion) based on the same three variables and are published as lookup tables. The Kattan nomograms predict recurrence after surgery and/or radiation therapy, based on data available at the time of diagnosis or after surgery. The Kattan score represents the likelihood of remaining free of disease at a given time interval following treatment.",
        "wiki_id": "88078"
    },
    {
        "id": "wiki20220301en004_21197",
        "title": "Prostate cancer",
        "content": "The UCSF Cancer of the Prostate Risk Assessment (CAPRA) score predicts both pathologic status and recurrence after surgery. It offers accuracy comparable to the Kattan preoperative nomogram and can be calculated without tables or a calculator. Points are assigned based on PSA, grade, stage, age, and percentage of cores positive; the sum yields a 0–10 score, with every two points representing roughly a doubling of risk of recurrence. The CAPRA score was derived from community-based data in the CaPSURE database. It has been validated among over 10,000 prostatectomy patients, including patients from CaPSURE; the SEARCH registry, representing data from several Veterans Health Administration and military medical centers; a multi-institutional cohort in Germany; and the prostatectomy cohort at Johns Hopkins University. More recently, it has been shown to predict metastasis and mortality following prostatectomy, radiation therapy, watchful waiting, or androgen deprivation therapy.",
        "contents": "Prostate cancer. The UCSF Cancer of the Prostate Risk Assessment (CAPRA) score predicts both pathologic status and recurrence after surgery. It offers accuracy comparable to the Kattan preoperative nomogram and can be calculated without tables or a calculator. Points are assigned based on PSA, grade, stage, age, and percentage of cores positive; the sum yields a 0–10 score, with every two points representing roughly a doubling of risk of recurrence. The CAPRA score was derived from community-based data in the CaPSURE database. It has been validated among over 10,000 prostatectomy patients, including patients from CaPSURE; the SEARCH registry, representing data from several Veterans Health Administration and military medical centers; a multi-institutional cohort in Germany; and the prostatectomy cohort at Johns Hopkins University. More recently, it has been shown to predict metastasis and mortality following prostatectomy, radiation therapy, watchful waiting, or androgen deprivation therapy.",
        "wiki_id": "88078"
    },
    {
        "id": "wiki20220301en190_43919",
        "title": "Biochemical recurrence",
        "content": "Biochemical recurrence is a rise in the blood level of prostate-specific antigen (PSA) in prostate cancer patients after treatment with surgery or radiation. Biochemical recurrence may occur in patients who do not have symptoms. It may mean that the cancer has come back. Also called PSA failure and biochemical relapse. It is used to detect metastatic progression of the prostate cancer. References Further reading Guidelines:Prostate cancer/Management/Locally advanced and metastatic/Biochemical relapse alternative causes, and implications for treatment Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition 10 definitions compared. External links Biochemical recurrence entry in the public domain NCI Dictionary of Cancer Terms Oncology",
        "contents": "Biochemical recurrence. Biochemical recurrence is a rise in the blood level of prostate-specific antigen (PSA) in prostate cancer patients after treatment with surgery or radiation. Biochemical recurrence may occur in patients who do not have symptoms. It may mean that the cancer has come back. Also called PSA failure and biochemical relapse. It is used to detect metastatic progression of the prostate cancer. References Further reading Guidelines:Prostate cancer/Management/Locally advanced and metastatic/Biochemical relapse alternative causes, and implications for treatment Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition 10 definitions compared. External links Biochemical recurrence entry in the public domain NCI Dictionary of Cancer Terms Oncology",
        "wiki_id": "14416443"
    },
    {
        "id": "wiki20220301en004_21194",
        "title": "Prostate cancer",
        "content": "In patients who undergo treatment, the most important clinical prognostic indicators of disease outcome are the stage, pretherapy PSA level, and Gleason score. The higher the grade and the stage, the poorer the prognosis. Nomograms can be used to calculate the estimated risk of the individual patient. The predictions are based on the experience of large groups of patients. A complicating factor is that the majority of patients have multiple independent tumor foci upon diagnosis, and these foci have independent genetic changes and molecular features. Because of this extensive inter-focal heterogeneity, it is a risk that the prognostication is set based on the wrong tumor focus.",
        "contents": "Prostate cancer. In patients who undergo treatment, the most important clinical prognostic indicators of disease outcome are the stage, pretherapy PSA level, and Gleason score. The higher the grade and the stage, the poorer the prognosis. Nomograms can be used to calculate the estimated risk of the individual patient. The predictions are based on the experience of large groups of patients. A complicating factor is that the majority of patients have multiple independent tumor foci upon diagnosis, and these foci have independent genetic changes and molecular features. Because of this extensive inter-focal heterogeneity, it is a risk that the prognostication is set based on the wrong tumor focus.",
        "wiki_id": "88078"
    },
    {
        "id": "wiki20220301en199_21778",
        "title": "KIAA1524",
        "content": "Clinical significance CIP2A is over-expressed in several common human malignancies including, human head and neck squamous cell carcinoma (HNSCC), colon cancer, gastric cancer, breast cancer, prostate cancer and lung cancer. Notably, in these cancer types CIP2A over-expression is observed with very high frequency; in breast cancer around 40% of cancer patients are over-expressing CIP2A whereas in all other studied cancer types the frequency is between 65-87 percent. In breast cancer CIP2A expression correlates with disease aggressivity whereas in gastric and lung cancer CIP2A expression predicts for poor patient survival. To date high CIP2A expression has been observed to predict poor patient prognosis in more than dozen human cancer types, which makes it one of the most frequently altered human oncoprotein with clinical relevance.",
        "contents": "KIAA1524. Clinical significance CIP2A is over-expressed in several common human malignancies including, human head and neck squamous cell carcinoma (HNSCC), colon cancer, gastric cancer, breast cancer, prostate cancer and lung cancer. Notably, in these cancer types CIP2A over-expression is observed with very high frequency; in breast cancer around 40% of cancer patients are over-expressing CIP2A whereas in all other studied cancer types the frequency is between 65-87 percent. In breast cancer CIP2A expression correlates with disease aggressivity whereas in gastric and lung cancer CIP2A expression predicts for poor patient survival. To date high CIP2A expression has been observed to predict poor patient prognosis in more than dozen human cancer types, which makes it one of the most frequently altered human oncoprotein with clinical relevance.",
        "wiki_id": "15353882"
    },
    {
        "id": "wiki20220301en075_60599",
        "title": "American Joint Committee on Cancer",
        "content": "Objectives The objectives of the AJCC are to: Facilitate a timely and rigorous, evidence-based process to support a biologically relevant system for classification and outcome prediction of cancer that is compatible with systems of cancer population surveillance. Proactively educate the oncology community through the development and delivery of effective programs and products to guide patient care. Promulgate research and serve as the clearinghouse to support the development of clinically relevant predictive tools, prognostic factors, and other indicators that classify and predict cancer. Foster collaborative relationships with AJCC member organizations and organizations with similar objectives in support of systems to diagnose and treat cancer. Support and be responsive to public and private efforts to improve care and predict outcomes for cancer patients. References http://cancerstaging.org/About/what-is-the-ajcc/Pages/whatisajcc.aspx External links Official page",
        "contents": "American Joint Committee on Cancer. Objectives The objectives of the AJCC are to: Facilitate a timely and rigorous, evidence-based process to support a biologically relevant system for classification and outcome prediction of cancer that is compatible with systems of cancer population surveillance. Proactively educate the oncology community through the development and delivery of effective programs and products to guide patient care. Promulgate research and serve as the clearinghouse to support the development of clinically relevant predictive tools, prognostic factors, and other indicators that classify and predict cancer. Foster collaborative relationships with AJCC member organizations and organizations with similar objectives in support of systems to diagnose and treat cancer. Support and be responsive to public and private efforts to improve care and predict outcomes for cancer patients. References http://cancerstaging.org/About/what-is-the-ajcc/Pages/whatisajcc.aspx External links Official page",
        "wiki_id": "3295323"
    },
    {
        "id": "wiki20220301en013_105238",
        "title": "Prediction market",
        "content": "Types Reputation-based Some prediction websites, sometimes classified as prediction markets, do not involve betting real money but rather add to or subtract from a predictor's reputation points based on the accuracy of a prediction. This incentive system may be better-suited than traditional prediction markets for niche or long-timeline questions. These include Metaculus and Good Judgment Open. A 2006 study found that real-money prediction markets were significantly more accurate than play-money prediction markets for non-sports events. Combinatorial prediction markets A combinatorial prediction market is a type of prediction market where participants can make bets on combinations of outcomes. The advantage of making bets on combinations of outcomes is that, in theory, conditional information can be better incorporated into the market price.",
        "contents": "Prediction market. Types Reputation-based Some prediction websites, sometimes classified as prediction markets, do not involve betting real money but rather add to or subtract from a predictor's reputation points based on the accuracy of a prediction. This incentive system may be better-suited than traditional prediction markets for niche or long-timeline questions. These include Metaculus and Good Judgment Open. A 2006 study found that real-money prediction markets were significantly more accurate than play-money prediction markets for non-sports events. Combinatorial prediction markets A combinatorial prediction market is a type of prediction market where participants can make bets on combinations of outcomes. The advantage of making bets on combinations of outcomes is that, in theory, conditional information can be better incorporated into the market price.",
        "wiki_id": "294496"
    },
    {
        "id": "wiki20220301en021_1500",
        "title": "Philadelphia chromosome",
        "content": "The ABL1 gene expresses a membrane-associated protein, a tyrosine kinase, and the BCR-ABL1 transcript is also translated into a tyrosine kinase containing domains from both the BCR and ABL1 genes. The activity of tyrosine kinases is typically regulated in an auto-inhibitory fashion, but the BCR-ABL1 fusion gene codes for a protein that is \"always on\" or constitutively activated, leading to impaired DNA binding and unregulated cell division (i.e. cancer). This is due to the replacement of the myristoylated cap region, which when present induces a conformational change rendering the kinase domain inactive, with a truncated portion of the BCR protein. Although the BCR region also expresses serine/threonine kinases, the tyrosine kinase function is very relevant for drug therapy. As the N-terminal Y177 and CC domains from BCR encode the constitutive activation of the ABL1 kinase, these regions are targeted in therapies to downregulate BCR-ABL1 kinase activity. Tyrosine kinase inhibitors",
        "contents": "Philadelphia chromosome. The ABL1 gene expresses a membrane-associated protein, a tyrosine kinase, and the BCR-ABL1 transcript is also translated into a tyrosine kinase containing domains from both the BCR and ABL1 genes. The activity of tyrosine kinases is typically regulated in an auto-inhibitory fashion, but the BCR-ABL1 fusion gene codes for a protein that is \"always on\" or constitutively activated, leading to impaired DNA binding and unregulated cell division (i.e. cancer). This is due to the replacement of the myristoylated cap region, which when present induces a conformational change rendering the kinase domain inactive, with a truncated portion of the BCR protein. Although the BCR region also expresses serine/threonine kinases, the tyrosine kinase function is very relevant for drug therapy. As the N-terminal Y177 and CC domains from BCR encode the constitutive activation of the ABL1 kinase, these regions are targeted in therapies to downregulate BCR-ABL1 kinase activity. Tyrosine kinase inhibitors",
        "wiki_id": "526659"
    },
    {
        "id": "wiki20220301en049_64020",
        "title": "Fusion gene",
        "content": "Oncogenes It has been known for 30 years that the corresponding gene fusion plays an important role in tumorgenesis. Fusion genes can contribute to tumor formation because fusion genes can produce much more active abnormal protein than non-fusion genes. Often, fusion genes are oncogenes that cause cancer; these include BCR-ABL, TEL-AML1 (ALL with t(12 ; 21)), AML1-ETO (M2 AML with t(8 ; 21)), and TMPRSS2-ERG with an interstitial deletion on chromosome 21, often occurring in prostate cancer. In the case of TMPRSS2-ERG, by disrupting androgen receptor (AR) signaling and inhibiting AR expression by oncogenic ETS transcription factor, the fusion product regulates the prostate cancer. Most fusion genes are found from hematological cancers, sarcomas, and prostate cancer. BCAM-AKT2 is a fusion gene that is specific and unique to high-grade serous ovarian cancer.",
        "contents": "Fusion gene. Oncogenes It has been known for 30 years that the corresponding gene fusion plays an important role in tumorgenesis. Fusion genes can contribute to tumor formation because fusion genes can produce much more active abnormal protein than non-fusion genes. Often, fusion genes are oncogenes that cause cancer; these include BCR-ABL, TEL-AML1 (ALL with t(12 ; 21)), AML1-ETO (M2 AML with t(8 ; 21)), and TMPRSS2-ERG with an interstitial deletion on chromosome 21, often occurring in prostate cancer. In the case of TMPRSS2-ERG, by disrupting androgen receptor (AR) signaling and inhibiting AR expression by oncogenic ETS transcription factor, the fusion product regulates the prostate cancer. Most fusion genes are found from hematological cancers, sarcomas, and prostate cancer. BCAM-AKT2 is a fusion gene that is specific and unique to high-grade serous ovarian cancer.",
        "wiki_id": "1822243"
    },
    {
        "id": "wiki20220301en072_33581",
        "title": "Targeted therapy",
        "content": "The most successful targeted therapies are chemical entities that target or preferentially target a protein or enzyme that carries a mutation or other genetic alteration that is specific to cancer cells and not found in normal host tissue. One of the most successful molecular targeted therapeutic is Gleevec, which is a kinase inhibitor with exceptional affinity for the oncofusion protein BCR-Abl which is a strong driver of tumorigenesis in chronic myelogenous leukemia. Although employed in other indications, Gleevec is most effective targeting BCR-Abl. Other examples of molecular targeted therapeutics targeting mutated oncogenes, include PLX27892 which targets mutant B-raf in melanoma. There are targeted therapies for lung cancer, colorectal cancer, head and neck cancer, breast cancer, multiple myeloma, lymphoma, prostate cancer, pancreatic cancer, melanoma and other cancers.",
        "contents": "Targeted therapy. The most successful targeted therapies are chemical entities that target or preferentially target a protein or enzyme that carries a mutation or other genetic alteration that is specific to cancer cells and not found in normal host tissue. One of the most successful molecular targeted therapeutic is Gleevec, which is a kinase inhibitor with exceptional affinity for the oncofusion protein BCR-Abl which is a strong driver of tumorigenesis in chronic myelogenous leukemia. Although employed in other indications, Gleevec is most effective targeting BCR-Abl. Other examples of molecular targeted therapeutics targeting mutated oncogenes, include PLX27892 which targets mutant B-raf in melanoma. There are targeted therapies for lung cancer, colorectal cancer, head and neck cancer, breast cancer, multiple myeloma, lymphoma, prostate cancer, pancreatic cancer, melanoma and other cancers.",
        "wiki_id": "3084027"
    },
    {
        "id": "article-27833_324",
        "title": "Prostate Cancer -- Prognosis -- Predictive Tables and Nomograms",
        "content": "Various predictive tables and nomograms are now available to help predict outcomes, positive lymph nodes, and survival after radical prostatectomy based on outcome data from multiple sources. These tools generally include some combination of age, Gleason score, biopsy information, and PSA levels and may also require other clinical information, such as the number of positive biopsies with the percentage of tumor involvement and clinical and pathological staging. [464] Multiple nomograms exist, including the Briganti, Rotterdam, and Stanford models. Three of the most popular nomograms available online for free include the following: Partin tables from Johns Hopkins University [465] [466] [467] Memorial Sloan Kettering Cancer Center prostate cancer nomograms [212] [468] Cancer of the Prostate Risk Assessment score from the University of California, San Francisco [469]",
        "contents": "Prostate Cancer -- Prognosis -- Predictive Tables and Nomograms. Various predictive tables and nomograms are now available to help predict outcomes, positive lymph nodes, and survival after radical prostatectomy based on outcome data from multiple sources. These tools generally include some combination of age, Gleason score, biopsy information, and PSA levels and may also require other clinical information, such as the number of positive biopsies with the percentage of tumor involvement and clinical and pathological staging. [464] Multiple nomograms exist, including the Briganti, Rotterdam, and Stanford models. Three of the most popular nomograms available online for free include the following: Partin tables from Johns Hopkins University [465] [466] [467] Memorial Sloan Kettering Cancer Center prostate cancer nomograms [212] [468] Cancer of the Prostate Risk Assessment score from the University of California, San Francisco [469]"
    },
    {
        "id": "wiki20220301en011_17560",
        "title": "B cell",
        "content": "B cells undergo two types of selection while developing in the bone marrow to ensure proper development, both involving B cell receptors (BCR) on the surface of the cell. Positive selection occurs through antigen-independent signaling involving both the pre-BCR and the BCR. If these receptors do not bind to their ligand, B cells do not receive the proper signals and cease to develop. Negative selection occurs through the binding of self-antigen with the BCR; If the BCR can bind strongly to self-antigen, then the B cell undergoes one of four fates: clonal deletion, receptor editing, anergy, or ignorance (B cell ignores signal and continues development). This negative selection process leads to a state of central tolerance, in which the mature B cells do not bind self antigens present in the bone marrow.",
        "contents": "B cell. B cells undergo two types of selection while developing in the bone marrow to ensure proper development, both involving B cell receptors (BCR) on the surface of the cell. Positive selection occurs through antigen-independent signaling involving both the pre-BCR and the BCR. If these receptors do not bind to their ligand, B cells do not receive the proper signals and cease to develop. Negative selection occurs through the binding of self-antigen with the BCR; If the BCR can bind strongly to self-antigen, then the B cell undergoes one of four fates: clonal deletion, receptor editing, anergy, or ignorance (B cell ignores signal and continues development). This negative selection process leads to a state of central tolerance, in which the mature B cells do not bind self antigens present in the bone marrow.",
        "wiki_id": "211941"
    },
    {
        "id": "wiki20220301en075_45288",
        "title": "Gleason grading system",
        "content": "The Gleason grading system is used to help evaluate the prognosis of men with prostate cancer using samples from a prostate biopsy. Together with other parameters, it is incorporated into a strategy of prostate cancer staging which predicts prognosis and helps guide therapy. A Gleason score is given to prostate cancer based upon its microscopic appearance. Cancers with a higher Gleason score are more aggressive and have a worse prognosis. Pathological scores range from 2 to 10, with higher numbers indicating greater risks and higher mortality. The system is widely accepted and used for clinical decision making even as it is recognised that certain biomarkers, like ACP1 expression, might yield higher predictive value for future disease course.",
        "contents": "Gleason grading system. The Gleason grading system is used to help evaluate the prognosis of men with prostate cancer using samples from a prostate biopsy. Together with other parameters, it is incorporated into a strategy of prostate cancer staging which predicts prognosis and helps guide therapy. A Gleason score is given to prostate cancer based upon its microscopic appearance. Cancers with a higher Gleason score are more aggressive and have a worse prognosis. Pathological scores range from 2 to 10, with higher numbers indicating greater risks and higher mortality. The system is widely accepted and used for clinical decision making even as it is recognised that certain biomarkers, like ACP1 expression, might yield higher predictive value for future disease course.",
        "wiki_id": "3279703"
    },
    {
        "id": "wiki20220301en013_6118",
        "title": "Prostate-specific antigen",
        "content": "Men with prostate cancer may be characterized as low-, intermediate-, or high-risk for having/developing metastatic disease or dying of prostate cancer. PSA level is one of three variables on which the risk-stratification is based; the others are the grade of prostate cancer (Gleason grading system) and the stage of cancer based on physical examination and imaging studies. D'Amico Criteria for each risk category are as follows: Low-risk: PSA < 10, Gleason score ≤ 6, AND clinical stage ≤ T2a Intermediate-risk: PSA 10-20, Gleason score 7, OR clinical stage T2b/c High-risk: PSA > 20, Gleason score ≥ 8, OR clinical stage ≥ T3 Given the relative simplicity of the 1998 D'Amico criteria (above), other predictive models of risk stratification based on mathematical probability constructs exist or have been proposed to allow for better matching of treatment decisions with disease features.",
        "contents": "Prostate-specific antigen. Men with prostate cancer may be characterized as low-, intermediate-, or high-risk for having/developing metastatic disease or dying of prostate cancer. PSA level is one of three variables on which the risk-stratification is based; the others are the grade of prostate cancer (Gleason grading system) and the stage of cancer based on physical examination and imaging studies. D'Amico Criteria for each risk category are as follows: Low-risk: PSA < 10, Gleason score ≤ 6, AND clinical stage ≤ T2a Intermediate-risk: PSA 10-20, Gleason score 7, OR clinical stage T2b/c High-risk: PSA > 20, Gleason score ≥ 8, OR clinical stage ≥ T3 Given the relative simplicity of the 1998 D'Amico criteria (above), other predictive models of risk stratification based on mathematical probability constructs exist or have been proposed to allow for better matching of treatment decisions with disease features.",
        "wiki_id": "267922"
    }
]